Company / Operating Income per Share
Spyre Therapeutics, Inc. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$3.48
FY2025
5-year range
-$92.69 / -$1.37
FY2021-FY2025
Trend
+39.9%
vs FY2024
Sector context
#150 of 201
Health Care
What the data says
Spyre Therapeutics, Inc.'s operating income per share of $-3.48 is lower than 75% of companies in the Health Care sector (FY2025). Operating Income per Share has fluctuated over the past 10 years, ranging from $-92.69 in FY2023 to $-1.15 in FY2019.
Based on SEC 10-K filings.
-3.48 in FY2025.
Improved from $-92.69 to $-3.48 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 201This company -$3.48 Sector average -$28.56
▼
+87.8% above sector average
Key checks
Key Insights
- In FY2025, operating income per share increased 39.9% year-over-year.
- Ranks #150 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2019.
- Lowest operating income per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.48 | +39.9% |
| FY2024 | -$5.78 | +93.8% |
| FY2023 | -$92.69 | -5514.7% |
| FY2022 | -$1.65 | -20.6% |
| FY2021 | -$1.37 | +12.4% |
| FY2020 | -$1.56 | -36.3% |
| FY2019 | -$1.15 | +12.8% |
| FY2018 | -$1.31 | +28.2% |
| FY2017 | -$1.83 | +18.2% |
| FY2016 | -$2.24 | +88.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026